Update in Breast Cancer Screening,Prevention,and Treatment

Nelson HD , Fu R , Cantor A , Pappas M , Daeges M , Humphrey L . Effectiveness of breast cancer screening: Systematic review and meta-analysis to update the 2009 U.S. preventive services task force recommendation. Ann Intern Med, 2016; 164:244–255.

Siu AL , U.S. Preventive Services Task Force. Screening for breast cancer: U.S. preventive services task force recommendation statement. Ann Intern Med, 2016; 164:279–296.

Oeffinger KC , Fontham ET , Etzioni R , et al. Breast cancer screening for women at average risk: 2015 Guideline update from the American Cancer Society. JAMA, 2015; 314:1599–1614.

Boyd NF , Guo H , Martin LJ , et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med, 2007; 356:227–236.

Mandelson MT , Oestreicher N , Porter PL , et al. Breast density as a predictor of mammographic detection: Comparison of interval- and screen-detected cancers. J Natl Cancer Inst, 2000; 92:1081–1087.

Wanders JO , Holland K , Veldhuis WB , et al. Volumetric breast density affects performance of digital screening mammography. Breast Cancer Res Treat, 2017; 162:95–103.

Kuhl CK . Abbreviated magnetic resonance imaging (MRI) for breast cancer screening: Rationale, concept, and transfer to clinical practice. Annu Rev Med, 2019; 70:501–519.

Cuzick J , Sestak I , Forbes JF , et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): An international, double-blind, randomised placebo-controlled trial. Lancet, 2014; 383:1041–1048. Erratum in: Lancet 2014;383(9922):1040. Erratum in: Lancet 2017;383:1010.

Goss PE , Ingle JN , Alés-Martínez JE , et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med, 2011; 364:2381–2391. Erratum in N Engl J Med 2011;364:1361.

Chlebowski RT , Kuller LH , Prentice RL et al . Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med, 2009; 360:573–587.

Manson JE , Chlebowshi RT , Stefanick ML , et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA, 2013; 310:1353–1368.

Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: Individual participant meta-analysis of the worldwide epidemiological evidence. Lancet, 2019; 394:1159–1168.

Beral V , Peto R , Pirie K , Reeves G . Menopuasal hormone therapy and 20 year breast cancer mortality. Lancet, 2019; 394:1139.

Bleyer A , Welch HG . Effect of three decades of screening mammography n breast-cance incidence. N Engl J Med, 2012; 367:1998–2005.

Youngwirth LM , Boughey JC , Hwang ES . Surgery versus monitoring and endocrine therapy for low-risk DCIS: The COMET trial. Bull Am Coll Surg, 2017; 102:62–63.